Muscarinic M1 receptor (CHRM1) positive allosteric modulators represent a promising approach to treating the cognitive deficits of schizophrenia. Hence, we decided to extend studies using cloned receptors and animal models to study CHRM1 orthoand allosteric binding in human cortex. Therefore, we measured the displacement of [3H]NMS(0.13nM) with acetylcholine(0—1mM) in the presence of BQCA (posi...

Patients: 148 people aged 18 to 55 years (mean age 39 years) diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder (manic or mixed episode) according to DSM-IV criteria. Main inclusion criteria were: agitated at baseline (as defined by a score of .20 points according to the Positive and Negative Syndrome Scale-Excited Component test (PANSS-EC; ...

Muscarinic M1 receptor (CHRM1) positive allosteric modulators represent a promising approach to treating the cognitive deficits of schizophrenia. Hence, we decided to extend studies using cloned receptors and animal models to study CHRM1 orthoand allosteric binding in human cortex. Therefore, we measured the displacement of [3H]NMS(0.13nM) with acetylcholine(0—1mM) in the presence of BQCA (posi...

Muscarinic M1 receptor (CHRM1) positive allosteric modulators represent a promising approach to treating the cognitive deficits of schizophrenia. Hence, we decided to extend studies using cloned receptors and animal models to study CHRM1 orthoand allosteric binding in human cortex. Therefore, we measured the displacement of [3H]NMS(0.13nM) with acetylcholine(0—1mM) in the presence of BQCA (posi...

OBJECTIVE Lurasidone is a novel psychotropic agent with high affinity for D(2) and 5-HT(2A) receptors, as well as for receptors implicated in the enhancement of cognition and mood and the reduction of negative symptoms (5-HT(7), 5-HT(1A), and alpha(2c)). The objective of the study was to evaluate the safety and efficacy of lurasidone in patients hospitalized for an acute exacerbation of DSM-IV-...

BACKGROUND To develop a pharmacokinetic-pharmacodynamic (PK-PD) model using individual-level data of Positive and Negative Syndrome Scale (PANSS) total score to characterize the antipsychotic drug effect taking into account the placebo effect and dropout rate. In addition, a clinical utility (CU) criterion that describes the usefulness of a drug therapy was calculated using the efficacy of the ...

BACKGROUND Abnormality in the concentration and functioning of gamma-aminobutyric acid (γ-aminobutyric acid, GABA) in the brain is not only an important hypothetical link to the cause of schizophrenia but it may also be correlated with the cognitive decline and negative symptoms of schizophrenia. Studies utilizing high field magnetic resonance spectroscopy (MRS) report abnormal density of GABA ...

Methods: Study subjects had a diagnosis of schizophrenia (DSM-IV-TR) with a duration of ≥2 years and had been clinically stable for ≥6 months but continued to have a Positive and Negative Syndrome Scale (PANSS) negative symptom score of ≥24 plus a score of ≥4 on at least 2 of the 4 core negative PANSS symptoms: blunted affect, passive social withdrawal, lack of spontaneity, and flow of conversa...

BACKGROUND We examined whether new structured professional judgment instruments for assessing need for therapeutic security, treatment completion and recovery in forensic settings were related to moves from higher to lower levels of therapeutic security and added anything to assessment of risk. METHODS This was a prospective naturalistic twelve month observational study of a cohort of patient...